Compelling Phase 2 Data and Prader–Willi Upside Support Buy Rating and Favorable Risk/Reward for DRUG

BTIG analyst Thomas Shrader has maintained their bullish stance on DRUG stock, giving a Buy rating on February 13.

Thomas Shrader has given his Buy rating due to a combination of factors, including compelling Phase 2 data for BMB-101 in difficult-to-treat epilepsies and a strong safety profile. The drug delivered substantial seizure reductions in both absence and developmental epileptic encephalopathy patients, alongside improvements in REM sleep and a lack of typical sedating side effects, underscoring meaningful clinical differentiation.

Shrader also points to the strategic expansion into Prader-Willi syndrome as an attractive upside driver, supported by a mechanistically aligned 5-HT2C agonist approach and a relatively low efficacy bar in a setting with limited options. With upcoming global registration plans, a planned Phase 2a PWS trial, and a solid cash position to fund development, he views the risk/reward as favorable and sees DRUG as well-positioned for value creation.

According to TipRanks, Shrader is a 4-star analyst with an average return of 4.6% and a 39.18% success rate. Shrader covers the Healthcare sector, focusing on stocks such as NRX Pharmaceuticals, Acumen Pharmaceuticals, and Bright Minds Biosciences.